Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuka Maeda

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2013
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humansDaisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda, et al.
Cancer Research|February 10, 2012
Intracellular tumor-associated antigens represent effective targets for passive immunotherapyTakuro Noguchi, Takuma Kato, Linan Wang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 25, 2010
Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cellsDaisuke Muraoka, Takuma Kato, Linan Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 20, 2014
Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancersKazuya Nagano, Yuka Maeda, So-Ichiro Kanasaki, et al.
JMIR Research Protocols|February 3, 2026
Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and OlanzapineAyako Higuchi, Yumiko Koi, Tomoaki Eto, et al.
Blood|February 11, 2012
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphomaHiroyoshi Nishikawa, Yuka Maeda, Takashi Ishida, et al.
Biochemical and Biophysical Research Communications|April 14, 2012
Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cellsTakuya Yamashita, Kazuya Nagano, So-ichiro Kanasaki, et al.
Nature Communications|December 15, 2021
Depletion of central memory CD8<sup>+</sup> T cells might impede the antitumor therapeutic effect of MogamulizumabYuka Maeda, Hisashi Wada, Daisuke Sugiyama, et al.
Nature Medicine|April 26, 2016
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancersTakuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, et al.
The Journal of Experimental Medicine|November 10, 2019
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cellsAtsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2013
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humansDaisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda, et al.
Cancer Research|February 10, 2012
Intracellular tumor-associated antigens represent effective targets for passive immunotherapyTakuro Noguchi, Takuma Kato, Linan Wang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 25, 2010
Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cellsDaisuke Muraoka, Takuma Kato, Linan Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 20, 2014
Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancersKazuya Nagano, Yuka Maeda, So-Ichiro Kanasaki, et al.
JMIR Research Protocols|February 3, 2026
Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and OlanzapineAyako Higuchi, Yumiko Koi, Tomoaki Eto, et al.
Blood|February 11, 2012
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphomaHiroyoshi Nishikawa, Yuka Maeda, Takashi Ishida, et al.
Biochemical and Biophysical Research Communications|April 14, 2012
Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cellsTakuya Yamashita, Kazuya Nagano, So-ichiro Kanasaki, et al.
Nature Communications|December 15, 2021
Depletion of central memory CD8<sup>+</sup> T cells might impede the antitumor therapeutic effect of MogamulizumabYuka Maeda, Hisashi Wada, Daisuke Sugiyama, et al.
Nature Medicine|April 26, 2016
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancersTakuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, et al.
The Journal of Experimental Medicine|November 10, 2019
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cellsAtsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, et al.
Pageof 6